Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
  • Patent number: 11000560
    Abstract: The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant T-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope. The oncolytic adenoviruses may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 11, 2021
    Assignee: VCN BIOSCIENCES, S.L.
    Inventors: Ramon Alemany, Raul Gil, Miriam Bazan
  • Patent number: 10994028
    Abstract: Methods for preparing highly purified rLV vector formulations at the scale needed to meet anticipated demand for human gene therapy are provided.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 4, 2021
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 10975425
    Abstract: A novel assay and a suite of devices may isolate nucleic acids from prokaryotic and eukaryotic cells and prepare samples for real-time (quantitative) polymerase chain reaction (PCR) analysis. The assay may employ an aqueous-based non-alcohol approach that yields robust RNA quality. The suite of ready-to-use devices may provide pre-loaded reagents in liquid and lyophilized formats to enable rapid manual operation in a laboratory or remote field environments. The assay and devices may be particularly suitable to analysis in microgravity or deep space environments.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: April 13, 2021
    Assignee: United States of America as Represented by the Administrator of NASA
    Inventors: Travis David Boone, Jimmy Kar Chuen Jung, Macarena Parra, Mark Brown
  • Patent number: 10975138
    Abstract: Production of etanercept using perfusion methods achieves attractive yields of properly folded protein. Desired temperature, feed media, titers and percent correctly folded protein are disclosed.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: April 13, 2021
    Assignee: Coherus BioSciences, Inc.
    Inventors: Ela Puchacz, James Russell Grove
  • Patent number: 10928383
    Abstract: A method for predicting an effect of a medication or a treatment regimen to a subject suffering from a cancer, the method comprises: (A) obtaining a tissue from the subject; (B) dissociating the tissue to obtain a multicellular cluster, wherein the multicellular cluster comprises the cancer cell; (C) culturing the multicellular cluster on a cellulose sponge; (D) exposing the cultured multicellular cluster to the medication or the treatment regimen; and (E) measuring a first survival rate of the cancer cell before exposing to the medication or the treatment regimen and a second survival rate of the cancer cell after exposing to the medication or the treatment regimen, when the second survival rate is lower than the first survival rate, the method predicts positive effect of the medication or the treatment regimen to the subject.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: February 23, 2021
    Inventors: Chih-Chiang Hsieh, Yen Chang
  • Patent number: 10920215
    Abstract: The present invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and DNA glycosylase with sufficiently low reactivity with a DNA having an unrelaxed double helix structure (unrelaxed DNA) are bonded, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 16, 2021
    Assignee: National University Corporation Kobe University
    Inventors: Keiji Nishida, Akihiko Kondo
  • Patent number: 10829787
    Abstract: Provided herein are compositions and methods useful, inter alia, for the delivery of ribonucleoprotein complexes (e.g., Cas9/guide RNA complexes) into cells. The compositions and methods provided herein are particularly useful for the delivery of ribonucleoprotein complexes into pluripotent cells and lymphatic cells.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 10, 2020
    Inventors: Xin Yu, Xiquan Liang, Xavier de Mollerat du Jeu, Robert Jason Potter
  • Patent number: 10799568
    Abstract: The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g. cancer, by adenoviral vectors which have been coated by polypeptides causing peptide-specific immune response. Also the present invention relates to a method of coating adenoviral vectors by specific peptides as well as to a method of identifying those peptides suitable for coating the capsid of an adenoviral vector.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: October 13, 2020
    Inventors: Vincenzo Cerullo, Markus Vähä-Koskela, Mari Hirvinen, Cristian Capasso
  • Patent number: 10793924
    Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: October 6, 2020
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
  • Patent number: 10745715
    Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
  • Patent number: 10744198
    Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites).
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: August 18, 2020
    Assignee: Najit Technologies, Inc.
    Inventors: Ian J. Amanna, Elizabeth A. Poore
  • Patent number: 10696960
    Abstract: A fusion protein comprising factor VII (FVII) and transferrin according to the present invention has an improved specific activity of FVII compared to existing FVII fusion proteins comprising other fusion partners than transferrin, and thus can be effectively used in a therapy using FVII.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: June 30, 2020
    Assignee: TiumBio Co., Ltd.
    Inventors: In-Young Song, Hun-Taek Kim, Bong-Yong Lee, Mahn-Hoon Park, Ho-Soon Lee, Yun Jung Lim, Ji-Hye Lee, Seo Yeon Son, Min-Sun Kim
  • Patent number: 10676721
    Abstract: The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enzymes or fragments thereof for targeting a broad spectrum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: June 9, 2020
    Assignees: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: James J. Collins, Michael Koeris, Timothy Kuan-Ta Lu, Gregory Stephanopoulos, Christopher Jongsoo Yoon
  • Patent number: 10660943
    Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 26, 2020
    Assignee: The Rockefeller University
    Inventors: David Bikard, Luciano Marraffini
  • Patent number: 10639364
    Abstract: The present invention belongs to the field of animal health and provides means to study Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. In a first consideration, the invention relates to a new PRRS virus variant. and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone. Based on this, new PRRS vaccine candidates with improved properties are provided.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 5, 2020
    Inventors: Andreas Gallei, Christoph Keller, Erik Schacht, Marieke Herrel
  • Patent number: 10626394
    Abstract: Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: April 21, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Sebastien Lemire, Andrew C. Yang, Kevin M. Yehl
  • Patent number: 10618947
    Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: April 14, 2020
    Inventors: Stephan Urban, Yi Ni
  • Patent number: 10610552
    Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 7, 2020
    Assignee: NCH Corporation
    Inventors: Gabriel F. K. Everett, Charles Greenwald, Judy Pruitt, Amanda Rosmarin, Jordan Church, Daniel Aberle, George Aboagye
  • Patent number: 10588957
    Abstract: The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: March 17, 2020
    Assignee: LEUKOCARE AG
    Inventors: Martin Scholz, Jens Altrichter, Kristina Kemter, Regina Scherliess, Hartwig Steckel
  • Patent number: 10577590
    Abstract: The present invention relates to a novel bacteriophage ?CJ28 (KCCM11466P) and a composition containing the same as an active ingredient. Further, the present invention relates to a method for preventing and/or treating infective diseases caused by enterotoxic Escherichia coli (ETEC) of animals excluding humans by using the composition.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 3, 2020
    Inventors: Eun Mi Shin, Gi Duk Bae, Jae Won Kim
  • Patent number: 10577591
    Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 3, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
  • Patent number: 10550384
    Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: February 4, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
  • Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • Patent number: 10526393
    Abstract: The present invention relates to a method for promoting virus infection and increasing virus production, by using a cell line having lost Bst2 gene functions and, more specifically, to a method for promoting target virus infection and increasing target virus production, in addition to promoting virus budding and inhibiting host cell apoptosis by removing the Bst2 gene from a cell line having the ability to produce a virus. According to the present invention, the method for promoting target virus infection and increasing target virus production, by using an animal cell line having lost Bst2 gene functions, can improve production yields of a target virus and an antigen protein, and thus can be useful for the preparation of vaccines for treating and preventing viral diseases.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 7, 2020
    Assignee: IMMUNOMAX CO., LTD.
    Inventors: Se-Ho Park, Eunbi Yi
  • Patent number: 10494402
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Patent number: 10487309
    Abstract: Methods are generally disclosed for attaching a cell binding motif to a carboxy end of a coat protein of a Tobacco Mosaic Virus particle to form a modified-TMV particle; and attaching a cell to the cell binding motif of the modified-TMV particle. Methods are also disclosed for incorporated virus particles, e.g., TMV virus particles into hydrogels.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 26, 2019
    Assignee: University of South Carolina
    Inventors: Qian Wang, Lim Andrew Lee
  • Patent number: 10480010
    Abstract: The present invention relates to an optimized baculovirus construct useful for the production of virus(-like) particles or viral vectors, in particular viral vectors for gene therapy.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: November 19, 2019
    Assignee: GENETHON
    Inventors: Lionel Galibert, Otto-Wilhelm Merten, Monique Van Oers, Christel Riviere
  • Patent number: 10463718
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 5, 2019
    Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny McIntosh, Edward Tuddenham
  • Patent number: 10435669
    Abstract: The invention relates to the field of microbiology, specifically to a bacteriophage, polypeptide and a corresponding polynucleotide, a nucleic acid molecule and/or vector and/or cell comprising such polynucleotide, a composition comprising said bacteriophage, polypeptide, polynucleotide, construct, vector and/or cell, preferably for preventing, treating or diagnosing contamination with and/or a condition in an individual related to Salmonella. The invention further relates to an antimicrobial composition for medical use or for use as a food additive or as a disinfectant, or for detecting bacteria, preferably in a diagnostic application, wherein said antimicrobial composition comprises a bacteriophage, polypeptide, corresponding polynucleotide, construct and/or vector and/or cell comprising such polypeptide and/or composition according to the present invention.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: October 8, 2019
    Assignee: MICREOS B.V.
    Inventors: Martin Johannes Loessner, Steven Hagens, Albert Johannes Hendrikus Slijkhuis, Jochen Achim Klumpp, Roger Marti
  • Patent number: 10435691
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 8, 2019
    Inventors: Samir Amrane, Jean-Louis Mergny, Amina Bedrat
  • Patent number: 10391163
    Abstract: A vaccine composition is disclosed. The vaccine composition comprises: (a) a therapeutically effective amount of an influenza virus-like particle (VLP) comprising: (i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; (b) Foot-and-mouth disease virus (FMDV) capsid protein VP3, recombinant FMDV VP3 (rVP3), VP3 peptide, or SUMO VP3; and (c) alum. Also disclosed is use of a vaccine composition according to the invention in the manufacture of a medicament for inducing an immunogenic response in a subject in need thereof.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 27, 2019
    Assignee: Academia Sinica
    Inventors: Shu-Mei Liang, Pei-Wen Hsiao, Ming-Chu Cheng, Yu-Chih Yang
  • Patent number: 10328109
    Abstract: Described herein is an adenovirus comprising an AB-loop comprising a targeting motif and methods of making and using the adenovirus. The targeting motif of the adenovirus can selectively bind to a tumor cell. The targeting motif of the adenovirus can selectively bind to cell markers and/or cell surface antigens including, for example, CD 133.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 25, 2019
    Inventor: Masato Yamamoto
  • Patent number: 10322172
    Abstract: A live, attenuated HIV vaccine is provided, and methods of making a attenuated HIV vaccine are provided.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: June 18, 2019
    Assignee: NUtech Ventures
    Inventors: Jiantao Guo, Qingsheng Li, Wei Niu, Yue Li, Nanxi Wang
  • Patent number: 10316334
    Abstract: CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 11, 2019
    Assignee: Oregon Health & Science University
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli
  • Patent number: 10309969
    Abstract: The present invention relates to a method for constructing an Fv library based on a combination of proteins, a method of screening a desired antibody using the constructed Fv library, an Fv antibody screened by the screening method, and an Fv library constructed by the Fv library construction method. The Fv library of the present invention is based on a combination of proteins so that members thereof can be individually analyzed for their function. Moreover, the Fv library enables a desired Fv antibody to be screened without needing a target antigen preparation. In addition, the protein combination based Fv library makes it possible to significantly reduce the number of protein purification processes to thereby reduce costs and time, compared to conventional DNA-based libraries.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 4, 2019
    Assignee: AbTLAS CO., LTD.
    Inventors: Byeong Doo Song, Jee Sun Yun, Song Yi Lee, Hye In Kim, Hyo Jung Choi, Jong Rip Choi
  • Patent number: 10301360
    Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: May 28, 2019
    Inventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
  • Patent number: 10272032
    Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 30, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventor: Janik Adriaansen
  • Patent number: 10267799
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 23, 2019
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10253072
    Abstract: The present invention is intended to provide an egg drop syndrome (EDS) vaccine that is capable of effectively preventing EDS and can be stably supplied. The EDS vaccine provided to this end contains as an active ingredient fused protein in which a polypeptide having a coiled-coil forming unit is bound to the knob region in the fiber protein of EDS virus (EDSV).
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: April 9, 2019
    Assignee: KM Biologics Co., Ltd.
    Inventors: Kenichi Yamazaki, Kiyohiko Andoh, Ryuichi Sakamoto, Kiyotaka Suenaga, Takeshi Arakawa, Hirotaka Uefuji, Tetsuya Harakuni, Takeshi Miyata
  • Patent number: 10208292
    Abstract: Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: February 19, 2019
    Assignee: Sanofi Pasteur Biologics, LLC
    Inventors: Simon Delagrave, CharChang Lai
  • Patent number: 10208304
    Abstract: Described herein is a method that generally includes infecting a host cell with a rescue adenovirus, wherein the rescue adenovirus genome comprises a loxP site and encodes at least one marker, and wherein the host cell comprises a library of polynucleotides that complement the adenovirus genome marker and encode a detectable polypeptide; incubating the infected host cell under conditions effective to permit recombination between the adenovirus genome and one or more of the library polynucleotides and the production of recombinant adenovirus particles comprising at least on detectable polypeptide; and detecting the at least one detectable polypeptide. Also described are adenovirus libraries constructed using such a method.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: February 19, 2019
    Inventors: Masato Yamamoto, Yoshiaki Miura
  • Patent number: 10202423
    Abstract: A method of producing a picornavirus-like particle (PVLP) in a plant is provided. The method comprises introducing a first nucleic acid and a second nucleic acid into the plant, portion of the plant, or a plant cell. The first nucleic acid comprising a first regulatory region active in the plant operatively linked to a nucleotide sequence encoding a polyprotein. The second nucleic acid comprises a second regulatory region active in the plant and operatively linked to a nucleotide sequence encoding one or more protease. The plant, portion of the plant, or plant cell is incubated under conditions that permit the expression of the nucleic acids, thereby producing the PVLP. A PVLP comprising the polyprotein is also provided.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 12, 2019
    Assignee: Medicago Inc. of Quebec, Canada
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie, Manon Couture, Lucie Poulin, Louis-Philippe Vezina
  • Patent number: 10195272
    Abstract: A chimeric antigen receptor (CAR) contains a human Fc?RI? extracellular domain or a mutant Fc?RI? extracellular domain that has a reduced binding affinity for human IgE compared to wild type human Fc?RI? extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: February 5, 2019
    Assignee: The Nemours Foundation
    Inventor: Zhengyu Ma
  • Patent number: 10190098
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: January 29, 2019
    Assignee: UniQure IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria C Hermens
  • Patent number: 10188723
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 29, 2019
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 10179112
    Abstract: The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: January 15, 2019
    Assignee: The Regents of the University of California
    Inventors: Yunfeng Lu, Ming Yan, Irvin S. Y. Chen, Min Liang
  • Patent number: 10160979
    Abstract: The present invention can induce stronger cellular immunity to hepatitis C and provide a treatment means and a prevention means that are effective in completely eliminating the hepatitis C virus (HCV). Provided is a pharmaceutical composition for the treatment and/or prevention of hepatitis C, said composition comprising a recombinant vaccinia virus (a) and a recombinant vector (b) and characterized in that after one of the recombinant vaccinia virus (a) and the recombinant vector (b) is administered for initial immunity, the other is administered for additional immunity. The recombinant vaccinia virus (a) contains an expression promoter and all or a portion of the cDNA of the HCV genome. The recombinant vector (b) contains an expression promoter and all or a portion of the cDNA of the HCV (where the cDNA contained in the recombinant vector (b) has a different base sequence than that included in the recombinant vaccinia virus (a)).
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: December 25, 2018
    Assignees: Tokyo Metropolitan Institute of Medical Science, National Institutes of Biomedical Innovation, Health and Nutrition, KM Biologics Co., Ltd.
    Inventors: Michinori Kohara, Yasuhiro Yasutomi, Yumiko Shiogama
  • Patent number: 10150805
    Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 11, 2018
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
  • Patent number: 10125402
    Abstract: Methods for the measuring cell-free nucleic acids and/or virus particles from dried blood spots are described. The methods can include the steps of rehydrating a dried blood sample, optionally fixing cells present in the rehydrated dried blood sample, eluting cell-free virus particles from the rehydrated dried blood sample, separating the cell-free viruses from any cell debris that may be present in the rehydrated dried blood sample by way of a filter, and measuring cell-free virus particles by a viral particle quantification technique.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 13, 2018
    Inventors: Paul Baum, Megan M. Crask, Xiaoning Wu
  • Patent number: RE47768
    Abstract: The present invention relates to virus growth media that improve the yield of alpha-herpesviruses (e.g., HSV-2) grown in cell cultures. The growth media of the invention include two additives, a disaccharide and a lipid mixture, that can be added to serum-free or serum-enriched growth media to improve the efficiency of virus production. The invention further provides methods of producing alpha-herpesviruses (e.g., HSV-2) in such growth media.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: December 17, 2019
    Assignee: Sanofi Pasteur Biologics LLC
    Inventors: Simon Delagrave, Rachid Oubelaid, John Hamberger